140 related articles for article (PubMed ID: 7541496)
41. Cytosolic components of the respiratory burst oxidase: resolution of four components, two of which are missing in complementing types of chronic granulomatous disease.
Curnutte JT; Scott PJ; Mayo LA
Proc Natl Acad Sci U S A; 1989 Feb; 86(3):825-9. PubMed ID: 2915980
[TBL] [Abstract][Full Text] [Related]
42. Molecular genetics of chronic granulomatous disease.
Dinauer MC; Orkin SH
Immunodefic Rev; 1988; 1(1):55-69. PubMed ID: 3078710
[TBL] [Abstract][Full Text] [Related]
43. Chronic granulomatous disease with partial deficiency of cytochrome b558 and incomplete respiratory burst: variants of the X-linked, cytochrome b558-negative form of the disease.
Roos D; de Boer M; Borregard N; Bjerrum OW; Valerius NH; Seger RA; Mühlebach T; Belohradsky BH; Weening RS
J Leukoc Biol; 1992 Feb; 51(2):164-71. PubMed ID: 1431553
[TBL] [Abstract][Full Text] [Related]
44. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
Nunoi H; Ishibashi F
Hum Cell; 1999 Sep; 12(3):103-8. PubMed ID: 10695016
[TBL] [Abstract][Full Text] [Related]
45. Gene therapy for chronic granulomatous disease.
Kume A; Dinauer MC
J Lab Clin Med; 2000 Feb; 135(2):122-8. PubMed ID: 10695656
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis of the autosomal recessive forms of chronic granulomatous disease.
Curnutte JT
Immunodefic Rev; 1992; 3(2):149-72. PubMed ID: 1554499
[TBL] [Abstract][Full Text] [Related]
47. Lentiviral Gene Therapy of Chronic Granulomatous Disease: Functional Assessment of Universal and Tissue-Specific Promoters.
Yuan H; Wu X; Liu H; Chang LJ
Hum Gene Ther; 2023 Jan; 34(1-2):19-29. PubMed ID: 36274229
[TBL] [Abstract][Full Text] [Related]
48. Gene therapy for chronic granulomatous disease.
Goebel WS; Dinauer MC
Acta Haematol; 2003; 110(2-3):86-92. PubMed ID: 14583668
[TBL] [Abstract][Full Text] [Related]
49. Classification of chronic granulomatous disease.
Curnutte JT
Hematol Oncol Clin North Am; 1988 Jun; 2(2):241-52. PubMed ID: 2839457
[TBL] [Abstract][Full Text] [Related]
50. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients.
Köker MY; Camcıoğlu Y; van Leeuwen K; Kılıç SŞ; Barlan I; Yılmaz M; Metin A; de Boer M; Avcılar H; Patıroğlu T; Yıldıran A; Yeğin O; Tezcan I; Sanal Ö; Roos D
J Allergy Clin Immunol; 2013 Nov; 132(5):1156-1163.e5. PubMed ID: 23910690
[TBL] [Abstract][Full Text] [Related]
51. [A therapeutic approach towards chronic granulomatous disease].
Kawai T
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):437-46. PubMed ID: 25748127
[TBL] [Abstract][Full Text] [Related]
52. Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease.
Dinauer MC; Pierce EA; Erickson RW; Muhlebach TJ; Messner H; Orkin SH; Seger RA; Curnutte JT
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11231-5. PubMed ID: 1763037
[TBL] [Abstract][Full Text] [Related]
53. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease.
Goebel WS; Pech NK; Dinauer MC
Blood Cells Mol Dis; 2004; 33(3):365-71. PubMed ID: 15528159
[TBL] [Abstract][Full Text] [Related]
54. Progress toward effective gene therapy for chronic granulomatous disease.
Malech HL; Choi U; Brenner S
Jpn J Infect Dis; 2004 Oct; 57(5):S27-8. PubMed ID: 15507764
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic effects of proteoliposomes on X-linked chronic granulomatous disease: proof of concept using macrophages differentiated from patient-specific induced pluripotent stem cells.
Brault J; Vaganay G; Le Roy A; Lenormand JL; Cortes S; Stasia MJ
Int J Nanomedicine; 2017; 12():2161-2177. PubMed ID: 28356734
[TBL] [Abstract][Full Text] [Related]
56. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.
Barde I; Laurenti E; Verp S; Wiznerowicz M; Offner S; Viornery A; Galy A; Trumpp A; Trono D
Gene Ther; 2011 Nov; 18(11):1087-97. PubMed ID: 21544095
[TBL] [Abstract][Full Text] [Related]
57. O2- production by B lymphocytes lacking the respiratory burst oxidase subunit p47phox after transfection with an expression vector containing a p47phox cDNA.
Chanock SJ; Faust LR; Barrett D; Bizal C; Maly FE; Newburger PE; Ruedi JM; Smith RM; Babior BM
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10174-7. PubMed ID: 1332032
[TBL] [Abstract][Full Text] [Related]
58. The p47phox mouse knock-out model of chronic granulomatous disease.
Jackson SH; Gallin JI; Holland SM
J Exp Med; 1995 Sep; 182(3):751-8. PubMed ID: 7650482
[TBL] [Abstract][Full Text] [Related]
59. Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art.
Connelly JA; Marsh R; Parikh S; Talano JA
J Pediatric Infect Dis Soc; 2018 May; 7(suppl_1):S31-S39. PubMed ID: 29746680
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic Testing for Chronic Granulomatous Disease.
Kuhns DB
Methods Mol Biol; 2019; 1982():543-571. PubMed ID: 31172495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
